The Vermedx® Diabetes Information System (VDIS) is a patented technology that provides measurable quality improvement and cost savings for patients, providers, and payers. VDIS is used by hospital systems, managed care organizations, and public health agencies, with results that consistently support the findings from a five-year clinical trial sponsored by the National Institutes of Health
VDIS has two core components:
A proprietary Registry System driven by laboratory test data that requires no data input from clinicians or public health staff. The System’s reports enable providers, payers, and public health agency officials to accurately assess the extent of disease and the quality of care for their entire diabetes population.
The Vermedx® Treatment Outreach System providing user-friendly clinical decision support and treatment optimization tools for providers and patients. These tools promote focus of care on the highest risk patients and enhance timely patient compliance with best practices.
For more information on how Vermedx® differs from traditional Population management technology, please review our Vermedx white paper.
Since March of 2007 we have been working with the New York City Department of Health to deploy our technology as a core component of their initiative to combat what Health Commissioner Thomas Frieden, MD, and the New York Times have labeled a ”crisis that is becoming an epidemic”.
The San Antonio Metropolitan Health Department engaged us on May 8, 2008, to install and operate a pilot Diabetes Registry-based population surveillance program extending through September of 2009. The stated intention of the Texas State Legislature is to extend this program to other large metropolitan areas should the pilot program yield the expected results
The combination of empirical client experience over more than a year and validated clinical trial results indicates that Vermedx improves treatment process, significantly reduces patient treatment costs, and generates substantial goodwill from both clinicians and patients.
Official and detailed publication of these results in leading medical journals is anticipated later in 2008. Please contact us for copies as they become available!
In addition to continually refining our diabetes surveillance and treatment technology, we are researching additional applications in related chronic disease domains. The Vermedx® system is the exclusive property of Vermont Clinical Decision Support, LLC, Burlington, Vermont, 05406.